Last reviewed · How we verify
Placebo matched to Rifampin
Placebo matched to Rifampin is a Bacterial RNA polymerase inhibitor Small molecule drug developed by Hamilton Health Sciences Corporation. It is currently in Phase 3 development for Treatment of tuberculosis, Prophylaxis of meningococcal meningitis.
Rifampin is a bacterial RNA polymerase inhibitor.
Rifampin is a bacterial RNA polymerase inhibitor. Used for Treatment of tuberculosis, Prophylaxis of meningococcal meningitis.
At a glance
| Generic name | Placebo matched to Rifampin |
|---|---|
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Bacterial RNA polymerase inhibitor |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Rifampin works by binding to the beta subunit of bacterial RNA polymerase, thereby inhibiting RNA synthesis and ultimately leading to the death of the bacterial cell. This results in a decrease in the bacterial load and a reduction in the severity of symptoms associated with bacterial infections.
Approved indications
- Treatment of tuberculosis
- Prophylaxis of meningococcal meningitis
Common side effects
- Hepatotoxicity
- Thrombocytopenia
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics (PHASE4)
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes (PHASE1)
- Drug-drug Interaction Study of Gepotidacin (PHASE1)
- A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults (PHASE1)
- Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (PHASE2)
- Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid (PHASE3)
- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) (PHASE2)
- A Pilot Study of Inflammatory Markers in Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matched to Rifampin CI brief — competitive landscape report
- Placebo matched to Rifampin updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI
Frequently asked questions about Placebo matched to Rifampin
What is Placebo matched to Rifampin?
How does Placebo matched to Rifampin work?
What is Placebo matched to Rifampin used for?
Who makes Placebo matched to Rifampin?
What drug class is Placebo matched to Rifampin in?
What development phase is Placebo matched to Rifampin in?
What are the side effects of Placebo matched to Rifampin?
What does Placebo matched to Rifampin target?
Related
- Drug class: All Bacterial RNA polymerase inhibitor drugs
- Target: All drugs targeting Bacterial RNA polymerase
- Manufacturer: Hamilton Health Sciences Corporation — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of tuberculosis
- Indication: Drugs for Prophylaxis of meningococcal meningitis
- Compare: Placebo matched to Rifampin vs similar drugs
- Pricing: Placebo matched to Rifampin cost, discount & access